Sign in Subscribe
Immunotherapy

Elicio Therapeutics to Present Late-Breaking Data on Immunogenicity and Preclinical Efficacy at SITC Annual Meeting

Strategic Insights

— 1 min read

Elicio Therapeutics, a clinical-stage biotechnology company, announced plans to present late-breaking data on the immunogenicity and preclinical efficacy of its lead product candidate, ELI-002, at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting. The presentation will highlight the promising results from the ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancer.

Key Takeaways:

  • Elicio's lead product candidate, ELI-002, has shown promising results in the ongoing Phase 2 AMPLIFY-7P trial, with late-breaking data to be presented at the SITC Annual Meeting.
  • The trial aims to evaluate the safety and efficacy of ELI-002 in patients with mKRAS-driven pancreatic cancer, a disease with limited treatment options.
  • ELI-002 is an off-the-shelf immunotherapy candidate that targets the most common KRAS mutations, which drive approximately 25% of all solid tumors.
  • Elicio's Amphiphile (AMP) technology aims to enhance the education, activation, and amplification of cancer-specific T cells, promoting durable cancer immunosurveillance in patients.
  • The company plans to expand ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers.
  • Elicio's pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively.

Statistics:

  • Approximately 25% of all solid tumors are driven by mutations in the KRAS-gene.
  • ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer (NCT05726864).
  • The updated AMPLIFY-201 Phase 1 data for PDAC and CRC included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population.

Sources:

  • GlobeNewswire. (2025, November 3). Elicio Therapeutics to Present Late-Breaking Data on Immunogenicity and Preclinical Efficacy of Its Lead Product Candidate, ELI-002, at SITC Annual Meeting [Press Release].
  • Elicio Therapeutics. (2025, November 3). Elicio Therapeutics to Present at the 2025 SITC Annual Meeting [Investor Presentation].

Read more